EA000626B3 - Синергические комбинации зидовудина, 1592u89 и зтс или ftc - Google Patents

Синергические комбинации зидовудина, 1592u89 и зтс или ftc

Info

Publication number
EA000626B3
EA000626B3 EA199700203A EA199700203A EA000626B3 EA 000626 B3 EA000626 B3 EA 000626B3 EA 199700203 A EA199700203 A EA 199700203A EA 199700203 A EA199700203 A EA 199700203A EA 000626 B3 EA000626 B3 EA 000626B3
Authority
EA
Eurasian Patent Office
Prior art keywords
cis
amino
oxathiolan
pyrimidin
hydroxymethyl
Prior art date
Application number
EA199700203A
Other languages
English (en)
Other versions
EA199700203A1 (ru
EA000626B1 (ru
Inventor
Дейвид Уолтер Бэрри
Марта Хайдер Сейнт-Клэр
Original Assignee
ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26306774&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA000626(B3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9506490.3A external-priority patent/GB9506490D0/en
Priority claimed from GBGB9506489.5A external-priority patent/GB9506489D0/en
Application filed by ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД filed Critical ВАЙВ ХЕЛТКЕР ЮКей ЛИМИТЕД
Publication of EA199700203A1 publication Critical patent/EA199700203A1/ru
Publication of EA000626B1 publication Critical patent/EA000626B1/ru
Publication of EA000626B3 publication Critical patent/EA000626B3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Изобретение относится к области фармацевтики, более конкретно к лечению и/или профилактике ВИЧ-инфекции. Заявлен набор лекарств, состоящий из (1S,4R)-цис-4-[2-амино-6-(циклопропиламино)-9Н-пурин-9-ил]-2-циклопентен-1-метанола и (2R,цис)-4-амино-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1Н)-пиримидин-2-она или (2R,цис)-4-амино-5-фторо-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1Н)-пиримидин-2-она, или их физиологически приемлемых функциональных производных. Кроме того, изобретение относится к фармацевтическому препарату, состоящему из (1S,4R)-цис-4-[2-амино-6-(циклопропиламино)-9Н-пурин-9-ил]-2-циклопентен-1-метанола и (2R,цис)-4-амино-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1Н)-пиримидин-2-она в сочетании с одним или большим числом фармацевтически приемлемых носителей, а также к способу лечения или профилактики симптомов или эффектов ВИЧ-инфекции у инфицированного животного, предусматривающему использование указанных набора и фармацевтического препарата. Описано также применение (1S,4R)-цис-4-[2-амино-6-(циклопропиламино)-9Н-пурин-9-ил]-2-циклопентен-1-метанола либо одновременно, либо последовательно с а) зидовудином и (2R,цис)-4-амино-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1Н)-пиримидин-2-оном или б) зидовудином и (2R,цис)-4-амино-5-фторо-1-(2-гидроксиметил-1,3-оксатиолан-5-ил)-(1Н)-пиримидин-2-оном, и применение набора лекарств, включающего комбинации указанных соединений, в изготовлении лекарственного средства для лечения и/или профилактики ВИЧ-инфекции.
EA199700203A 1995-03-30 1996-03-28 Синергические комбинации зидовудина, 1592u89 и зтс или ftc EA000626B3 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9506490.3A GB9506490D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
GBGB9506489.5A GB9506489D0 (en) 1995-03-30 1995-03-30 Antiviral combinations
PCT/EP1996/001352 WO1996030025A1 (en) 1995-03-30 1996-03-28 Synergistic combinations of zidovudine, 1592u89 and 3tc or ftc

Publications (3)

Publication Number Publication Date
EA199700203A1 EA199700203A1 (ru) 1998-02-26
EA000626B1 EA000626B1 (ru) 1999-12-29
EA000626B3 true EA000626B3 (ru) 2016-04-29

Family

ID=26306774

Family Applications (1)

Application Number Title Priority Date Filing Date
EA199700203A EA000626B3 (ru) 1995-03-30 1996-03-28 Синергические комбинации зидовудина, 1592u89 и зтс или ftc

Country Status (36)

Country Link
US (1) US6417191B1 (ru)
EP (1) EP0817637B1 (ru)
JP (1) JP2954357B2 (ru)
KR (1) KR100542536B1 (ru)
CN (1) CN1103593C (ru)
AP (1) AP652A (ru)
AT (1) ATE220551T1 (ru)
AU (1) AU715213B2 (ru)
BR (3) BR9607851B1 (ru)
CA (1) CA2216634C (ru)
CZ (1) CZ295940B6 (ru)
DE (3) DE69622386T2 (ru)
DK (1) DK0817637T3 (ru)
EA (1) EA000626B3 (ru)
EE (1) EE04047B1 (ru)
ES (1) ES2179193T3 (ru)
FR (1) FR05C0022I2 (ru)
GE (1) GEP20022647B (ru)
HK (1) HK1009401A1 (ru)
HU (1) HU224010B1 (ru)
IL (1) IL117727A (ru)
LU (1) LU91171I2 (ru)
MX (1) MX9707316A (ru)
MY (1) MY115461A (ru)
NL (1) NL300195I2 (ru)
NO (2) NO313787B1 (ru)
NZ (1) NZ306419A (ru)
OA (1) OA10616A (ru)
PL (1) PL187085B1 (ru)
PT (1) PT817637E (ru)
RO (1) RO117995B1 (ru)
SI (1) SI0817637T1 (ru)
SK (1) SK283825B6 (ru)
TR (1) TR199701074T1 (ru)
UA (1) UA60293C2 (ru)
WO (1) WO1996030025A1 (ru)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ333099A (en) * 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
US6113920A (en) * 1996-10-31 2000-09-05 Glaxo Wellcome Inc. Pharmaceutical compositions
TW536403B (en) * 1997-03-24 2003-06-11 Glaxo Group Ltd An ethanol and ethylenediaminetetraacetic acid free pharmaceutical composition comprising lamivudine and exhibiting antimicrobial preservative efficacy
GB9709945D0 (en) * 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
BR9809127A (pt) * 1997-05-17 2000-08-01 Glaxo Group Ltd Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
AU769660B2 (en) * 1997-05-17 2004-01-29 Glaxo Group Limited Carbocyclic nucleoside hemisulfate and its use in treating viral infections
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
US6875773B1 (en) 1998-05-29 2005-04-05 Ben M. Dunn Combination therapy for treatment of FIV infection
AU4219799A (en) * 1998-05-29 1999-12-13 University Of Florida Combination therapy for treatment of fiv infection
GB9820417D0 (en) * 1998-09-18 1998-11-11 Glaxo Group Ltd Antiviral combinations
US6432966B2 (en) 1999-10-29 2002-08-13 Smithkline Beecham Corporation Antiviral combinations
US7074417B2 (en) * 2000-10-13 2006-07-11 Advancis Pharmaceutical Corporation Multiple-delayed release anti-viral product, use and formulation thereof
AP2220A (en) * 2001-05-11 2011-03-24 Cipla Medpro Pty Ltd Pharmaceutical composition.
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
ATE398455T1 (de) 2003-01-14 2008-07-15 Gilead Sciences Inc Zusammensetzungen und verfahren zur antiviralen kombinationstherapie
EP1608629A1 (en) 2003-03-24 2005-12-28 F. Hoffmann-La Roche Ag Benzyl-pyridazinons as reverse transcriptase inhibitors
US20070202119A1 (en) 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
CN101291905A (zh) 2005-10-19 2008-10-22 弗·哈夫曼-拉罗切有限公司 苯乙酰胺nnrt抑制剂
KR101475091B1 (ko) 2006-12-13 2014-12-22 에프. 호프만-라 로슈 아게 비뉴클레오시드 역전사 효소 억제제로서 2-(피페리딘-4-일)-4-페녹시- 또는 페닐아미노-피리미딘 유도체
SI2120878T1 (sl) * 2007-02-09 2014-12-31 Alphapharm Pty Ltd Dozirna oblika, ki vsebuje dve aktivni farmacevtski sestavini v različnih fizičnih oblikah
EP2982978A1 (en) 2009-05-27 2016-02-10 Immunaid Pty Ltd Methods of treating diseases
KR20170078868A (ko) 2010-01-27 2017-07-07 비이브 헬쓰케어 컴퍼니 항바이러스 치료
EP3038607A2 (en) 2013-08-29 2016-07-06 Teva Pharmaceutical Industries Ltd. Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir and a monolithic tablet comprising darunavir and ritonavir
CA2942877A1 (en) 2014-04-08 2015-10-15 Nitzan SHAHAR Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
CN117164657A (zh) 2014-08-12 2023-12-05 莫纳什大学 定向淋巴的前药
WO2017041139A1 (en) 2015-09-08 2017-03-16 Monash University Lymph directing prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
AU2018324037A1 (en) * 2017-08-29 2020-04-16 Monash University Lymphatic system-directing lipid prodrugs
US11304954B2 (en) 2017-12-19 2022-04-19 Puretech Lyt, Inc. Lipid prodrugs of mycophenolic acid and uses thereof
US11608345B1 (en) 2017-12-19 2023-03-21 Puretech Lyt, Inc. Lipid prodrugs of rapamycin and its analogs and uses thereof
KR20220149534A (ko) 2020-02-05 2022-11-08 퓨어테크 엘와이티, 아이엔씨. 신경스테로이드의 지질 전구약물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
EP0513917A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4724232A (en) * 1985-03-16 1988-02-09 Burroughs Wellcome Co. Treatment of human viral infections
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US5122517A (en) 1988-06-10 1992-06-16 Regents Of The University Of Minnesota Antiviral combination comprising nucleoside analogs
GB8815265D0 (en) * 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5204466A (en) 1990-02-01 1993-04-20 Emory University Method and compositions for the synthesis of bch-189 and related compounds
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
US5723490A (en) 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
US5869461A (en) 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
NZ333099A (en) 1996-06-25 2000-06-23 Glaxo Group Ltd synergistic combinations comprising 141W94, zidovudine and 3TC for use in the treatment of HIV
ATE230267T1 (de) 1996-06-25 2003-01-15 Glaxo Group Ltd Zusammensetzungen enthaltend vx478, zidovudine und 159u89 für die verwendung in der behandlung von hiv
DE10226522A1 (de) * 2002-06-14 2003-12-24 Degussa Verwendung von Übergangsmetallkomplexen mit stickstoffhaltigen mehrzähnigen Liganden als Bleichkatalysator und Bleichmittelzusammensetzung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992015309A1 (en) * 1991-03-06 1992-09-17 The Wellcome Foundation Limited Antiviral nucleoside combination
EP0513917A1 (en) * 1991-05-16 1992-11-19 Glaxo Group Limited Antiviral combinations containing nucleoside analogs
WO1993023021A2 (en) * 1992-05-13 1993-11-25 The Wellcome Foundation Limited Therapeutic combinations

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ANTIMICROB AGENTS CHEMOTHER, 37 (10). 1993. 2206-2211., XP000578786, MATHEZ D. ET AL.: "INFECTIOUS AMPLIFICATION OF WILD-TYPE HUMAN IMMUNODEFICIENCY VIRUS FROM PATIENTS' LYMPHOCYTES AND MODULATION BY REVERSE TRANSCRIPTASE INHIBITORS IN-VITRO", see abstract, see page 2210, column 2, paragraph 4 - page 2211, column 1, paragraph 1 *
PROC NATL ACAD SCI USA, 90 (12). 1993. 5653-5656., XP000578149, TISDALE M. ET AL.: "RAPID IN-VITRO SELECTION OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 RESISTANT TO 3' THIACYTIDINE INHIBITORS DUE TO A MUTATION IN THE YMDD REGION OF REVERSE TRANSCRIPTASE", see page 5654, column 2, paragraph 4 *
PROGRAM ABSTR INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, OCT 4-7 1994, P7, XP000579331, DALUGE S.M. ET AL.: "1592U89 succinate - a novel carbocyclic nucleoside analogue with potent, selective anti-HIV activity." see the whole document *
PROGRAM ABSTR INTERSCI CONF ANTIMICROB AGENTS CHEMOTHER, OCT 4-7 1994, P92, XP000579330, TISDALE M. ET AL.: "Anti-HIV activity of (1S,4R)-4[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-methanol (159U89)", see the whole document *
SCRIP WORLD PHARMACEUTICAL NEWS. NO. 1969, OCT 25, 1994, XP000578818, "New AIDS therapies at ICAAC; Triple therapy Fusion toxins Wellcome's 1592U89 Protease inhibitor prodrugs", see page 26, column 2, paragraph 2 *

Also Published As

Publication number Publication date
HK1009401A1 (en) 1999-09-10
EP0817637B1 (en) 2002-07-17
AP652A (en) 1998-06-19
IL117727A0 (en) 1996-07-23
OA10616A (en) 2001-03-15
JP2954357B2 (ja) 1999-09-27
CA2216634C (en) 2004-07-20
ATE220551T1 (de) 2002-08-15
NL300195I2 (nl) 2005-11-01
EA199700203A1 (ru) 1998-02-26
NL300195I1 (nl) 2005-08-01
TR199701074T1 (xx) 1998-02-21
RO117995B1 (ro) 2002-12-30
DE69622386D1 (de) 2002-08-22
HUP9801571A2 (hu) 1999-01-28
AP9701089A0 (en) 1997-10-31
CN1103593C (zh) 2003-03-26
HU224010B1 (hu) 2005-04-28
LU91171I2 (fr) 2005-07-04
FR05C0022I1 (ru) 2005-06-10
PL187085B1 (pl) 2004-05-31
NO974510L (no) 1997-09-29
DE69622386T2 (de) 2003-02-13
KR100542536B1 (ko) 2006-03-23
BR9607851A (pt) 1998-07-21
IL117727A (en) 1999-11-30
DK0817637T3 (da) 2002-11-11
DE122005000029I1 (de) 2005-10-06
SK129597A3 (en) 1998-07-08
SK283825B6 (sk) 2004-02-03
NO974510D0 (no) 1997-09-29
HUP9801571A3 (en) 2001-04-28
ES2179193T3 (es) 2003-01-16
MX9707316A (es) 1997-11-29
CA2216634A1 (en) 1996-10-03
AU5497296A (en) 1996-10-16
JPH10511682A (ja) 1998-11-10
MY115461A (en) 2003-06-30
EP0817637A1 (en) 1998-01-14
EE04047B1 (et) 2003-06-16
NO313787B1 (no) 2002-12-02
BRPI9607851B8 (pt) 2019-11-05
NO2005014I1 (no) 2005-06-06
CZ295940B6 (cs) 2005-12-14
CN1185110A (zh) 1998-06-17
EE9700240A (et) 1998-04-15
PL322532A1 (en) 1998-02-02
GEP20022647B (en) 2002-03-25
SI0817637T1 (en) 2002-10-31
BRPI9612992B1 (pt) 2020-08-04
NO2005014I2 (no) 2008-02-11
EA000626B1 (ru) 1999-12-29
BR9607851B1 (pt) 2009-01-13
FR05C0022I2 (ru) 2005-10-21
CZ309097A3 (cs) 1998-05-13
WO1996030025A1 (en) 1996-10-03
NZ306419A (en) 2000-01-28
PT817637E (pt) 2002-11-29
KR19980703420A (ko) 1998-11-05
UA60293C2 (ru) 2003-10-15
US6417191B1 (en) 2002-07-09
AU715213B2 (en) 2000-01-20
LU91171I9 (ru) 2018-12-28
DE122005000029I2 (de) 2006-04-27

Similar Documents

Publication Publication Date Title
EA000626B3 (ru) Синергические комбинации зидовудина, 1592u89 и зтс или ftc
JP5819951B2 (ja) セクシャルウェルネスを改善するための組成物
BR0209658A (pt) Derivados de 4-amino-5-fenil-7-1ciclobutil-pirrolo [2,3-d] pirimidina
NO20053817L (no) Preparater og fremgangsmater for antiviral kombinasjonsterapi.
BR0314236A (pt) Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
JPH0125A (ja) ｄｓＲＮＡと逆転写酵素インヒビターを含んで成るＨＩＶ感染治療のための医薬組成物
PT88985A (pt) Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
CA2459470A1 (en) Pharmaceutical composition comprising gabapentin or an analogue thereof and an .alpha.-aminoamide and its analgesic use
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
Mannis et al. Ibrutinib rash in a patient with 17p del chronic lymphocytic leukemia.
BR9808060A (pt) Composição farmacêutica, processos para tratamento de infecções virais pela administração de uma quantidade farmaceuticamente segura e eficaz de uma composição farmacêutica, uso da lamivudina ou um seu derivado farmaceuticamente aceitável, e, processo para a preparação de uma composição farmacêutica.
BRPI0415322A (pt) composição farmacêutica antiretroviral, processo para a preparação de uma composição farmacêutica antiretroviral, método para reduzir a carga de consumo de pìlulas para um paciente, método para aumentar a meia-vida in vivo de lamivudina e de zidovudina enquanto não afetando a meia-vida de nevirapina
AR040242A1 (es) Composiciones farmaceuticas
ES2678122T3 (es) Comprimidos bucales mucoadherentes para el tratamiento del herpes orofacial
WO2004028457A3 (en) PHARMACEUTICAL COMPOSITION FOR IMPROVED ADMINISTRATION OF HIV gp41-DERIVED PEPTIDES, AND ITS USE IN THERAPY
DE50202865D1 (de) Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel
BR9809127A (pt) Combinação, formulação farmacêutica, processo para o tratamento de uma infecção por hiv em um animal infectado, uso de (-) -(1s,4r)-4-[2-amino-6-(ciclopropil amino)-9h-purin-9-il)-2-ciclopenteno-1-metanol, e, pacote de paciente
CA2616592C (en) Zalcitabine (ddc) boosted lamivudine (3tc) compositions for antiretroviral therapy
ES2189964T3 (es) Combinaciones que comprenden vx478, zidovudina, y 1592u89 para uso en el tratamiento de infecciones por vih.
RU94045140A (ru) Фармацевтическая композиция для профилактики или лечения вирусных заболеваний, способ ее получения и применение антагониста брадикинина или его физиологически переносимой соли в качестве средства для профилактики или лечения вирусных заболеваний
RU2005138167A (ru) Противовирусное средство (варианты) и способ лечения на его основе
WO2020237248A8 (en) Compositions and methods for treating presbyopia
Qian et al. Interleukin-2 improves vascular functions in streptozotocin-induced diabetic rats
BR9809124A (pt) Combinação, formulação, farmacêutica, processo para o tratamento de uma infecção por hiv em um animal, infectado, uso de (-)-(1s, 4r)-4-[2-amino-6-(ciclopropilamino)-9h-purin-9-il)-2-cicl openteno-1-metanol, e, pacote de paciente

Legal Events

Date Code Title Description
ND4A Extension of term of a eurasian patent

Designated state(s): RU

PC4A Registration of transfer of a eurasian patent by assignment
LD4A Eurasian patent limited on request of patent holder (b3)
TK4A Corrections in published eurasian patents
ND4A Extension of term of a eurasian patent
MK4A Patent expired

Designated state(s): AM KZ KG MD TJ TM

MK4A Patent expired

Designated state(s): AZ

MK4A Patent expired

Designated state(s): BY RU